Identification and validation of the TRHDE-AS1/hsa-miR-449a/ADAMTS5 axis as a novel prognostic biomarker in prostate cancer
- PMID: 38818922
- DOI: 10.1002/biof.2083
Identification and validation of the TRHDE-AS1/hsa-miR-449a/ADAMTS5 axis as a novel prognostic biomarker in prostate cancer
Abstract
Despite advancements in cancer research, the prognostic implications of competing endogenous RNA (ceRNA) networks in prostate cancer (PCa) remain incompletely understood. This study aimed to elucidate the prognostic relevance of ceRNA networks in PCa, utilizing a comprehensive bioinformatics approach alongside experimental validation. After searching The Cancer Genome Atlas (TCGA) database, RNA sequencing (RNA-Seq) data were extracted to identify differentially expressed RNAs (DERs) between 491 PCa samples and 51 normal prostate tissues, following which a comprehensive bioinformatics strategy was implemented to construct a ceRNA network. An optimal prognostic signature comprising these DERs was then established and validated using TCGA data. In addition, functional validation was performed through RNA pull-down, dual-luciferase reporter assays, quantitative real-time PCR, and western blot analysis conducted in PC-3 and DU145 cell lines, thereby complementing the bioinformatics analysis. A total of 613 DERs, comprising 103 long noncoding RNAs (lncRNAs), 60 microRNAs (miRNAs), and 450 messenger RNAs (mRNAs), were identified and utilized in constructing a ceRNA network, which encompassed 23 lncRNAs, 9 miRNAs, and 52 mRNAs. An optimal prognostic signature was established, including VPS9D1 antisense RNA 1 (VPS9D1-AS1), miR-449a, cyclin-dependent kinase 5 regulatory subunit 1 (CDK5R1), targeting protein for Xklp2 (TPX2), solute carrier family 7 member 11 (SLC7A11), copine7 (CPNE7), and maternal embryonic leucine zipper kinase (MELK), yielding area under the curve (AUC) values exceeding 0.8 across training, validation, and entire datasets. Our experiments results revealed an interaction between lncRNA TRHDE antisense RNA 1 (TRHDE-AS1) and miR-449a and that miR-449a could target the ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5) mRNA. Knockdown of miR-449a significantly impeded cell proliferation, G1/S transition, migration and invasion, and promoted apoptosis in PC-3 and DU145 cells. Furthermore, knockdown of miR-449a notably downregulated protein expression of CDK4, cyclin D1, N-cadherin and vimentin, while upregulating protein expression of cleaved caspase-3 and E-cadherin. This study contributes to a deeper understanding of the prognostic-linked ceRNA network in PCa, providing fundamental insights that could improve diagnostic and therapeutic approaches for PCa management.
Keywords: competing endogenous RNA network; miR‐449a; prognosis; prostate cancer.
© 2024 International Union of Biochemistry and Molecular Biology.
Similar articles
-
The topological key lncRNA H2k2 from the ceRNA network promotes mesangial cell proliferation in diabetic nephropathy via the miR-449a/b/Trim11/Mek signaling pathway.FASEB J. 2019 Oct;33(10):11492-11506. doi: 10.1096/fj.201900522R. Epub 2019 Jul 23. FASEB J. 2019. PMID: 31336052
-
Comprehensive analysis of the LINC01122/TPD52 axis as a predictive biomarker in prostate adenocarcinoma.Sci Rep. 2025 May 8;15(1):16122. doi: 10.1038/s41598-025-98219-1. Sci Rep. 2025. PMID: 40341647 Free PMC article.
-
Long noncoding RNA SNHG7 contributes to cell proliferation, migration, invasion and epithelial to mesenchymal transition in non-small cell lung cancer by regulating miR-449a/TGIF2 axis.Thorac Cancer. 2020 Feb;11(2):264-276. doi: 10.1111/1759-7714.13245. Epub 2019 Dec 3. Thorac Cancer. 2020. PMID: 31793741 Free PMC article.
-
PSMA3-AS1: a promising LncRNA as a diagnostic and prognostic biomarker in human cancers.Gene. 2025 Aug 10;960:149521. doi: 10.1016/j.gene.2025.149521. Epub 2025 Apr 21. Gene. 2025. PMID: 40268123 Review.
-
Clinical Significance and Pathogenic Mechanisms of Long Non-Coding RNA TRPM2-AS in Cancers.Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251315625. doi: 10.1177/15330338251315625. Technol Cancer Res Treat. 2025. PMID: 39865876 Free PMC article. Review.
Cited by
-
Emerging roles and clinical perspectives of long noncoding RNAs in prostate cancer.Med Oncol. 2025 Jun 27;42(8):289. doi: 10.1007/s12032-025-02859-2. Med Oncol. 2025. PMID: 40576878 Review.
-
Application of non‑coding RNAs in tumors (Review).Mol Med Rep. 2025 Jun;31(6):164. doi: 10.3892/mmr.2025.13529. Epub 2025 Apr 11. Mol Med Rep. 2025. PMID: 40211701 Free PMC article. Review.
References
REFERENCES
-
- Saini S. PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol (Dordr). 2016;39(2):97–106.
-
- Yuk HD, Kwak C. Role of radical prostatectomy in the management of metastatic prostate cancer. 2018 2018: Management of Advanced Prostate Cancer.
-
- Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146(3):353–358.
-
- Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007;4(9):721–726.
-
- Zampetaki A, Albrecht A, Steinhofel K. Long non‐coding RNA structure and function: is there a link? Front Physiol. 2018;9:1201.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous